(HealthDay News) — Differential expression of long noncoding RNAs identified in prostate cancer cell lines, patient tissue samples, and patient urine samples can detect prostate cancer, according to a study published in the November issue of the Journal of Molecular Diagnostics.
Noting that there is a need to develop sensitive and specific biomarkers for the early detection of prostate cancer, Bongyong Lee, PhD, from the Sanford-Burnham Medical Research Institute in Orlando, FL, and colleagues conducted microarray analysis of RNA in prostate cancer cell lines, patient tissue samples, and patient urine samples.
The researchers identified a group of differentially expressed long noncoding RNAs in prostate cancer cell lines and patient samples. Six long noncoding RNAs were further characterized from prostatic adenocarcinoma tissue samples (Gleason score > 6) and compared with matched normal tissues. The markers were successfully detected in patient urine samples and were up-regulated compared with normal urine. In the human prostate cancer cell line PC3, but not in LNCaP, AK024556 (SPRY4-IT1) was highly up-regulated; cell proliferation and invasion were inhibited and cell apoptosis increased with siRNA knockdown of SPRY4-IT1 in PC3 cells. To detect long noncoding RNAs in primary prostatic adenocarcinoma tissue samples, chromogenic in situ hybridization assay was developed.
“We believe that these results will set the stage for more extensive studies to develop novel long noncoding RNA-based diagnostic assays for early prostate cancer detection and will help to distinguish benign prostate cancer from precancerous lesions,” the authors write.